$RMTG
Regenerative Medical Technology Group Inc. Stock $rmtg

$rmtg Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000121390022070224 Filed on November 09, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$541.3K	$374.4K	$165.0K
YoY Change	86.64%	126.83%
Cost Of Revenue	$184.4K	$109.4K	$88.52K
YoY Change	-14.16%	23.55%
Gross Profit	$356.9K	$265.0K	$76.52K
YoY Change	374.72%	246.31%
Gross Profit Margin	65.93%	70.79%	46.36%
Selling, General & Admin	$421.1K	$387.2K	$9.079M
YoY Change	-24.45%	-95.74%
% of Gross Profit	118.01%	146.12%	11864.85%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$50.56K	$39.88K	$12.95K
YoY Change	83.79%	207.97%
% of Gross Profit	14.17%	15.05%	16.92%
Operating Expenses	$471.7K	$427.1K	$9.092M
YoY Change	-19.36%	-95.3%
Operating Profit	-$114.8K	-$162.1K	-$9.015M
YoY Change	-77.47%	-98.2%
Interest Expense	-$945.9K	$1.183M	-$900.0K
YoY Change	-10.84%	-231.46%
% of Operating Profit
Other Income/Expense, Net			$0.00
YoY Change
Pretax Income	-$1.061M	-$1.344M	-$9.915M
YoY Change	-32.47%	-86.44%
Income Tax
% Of Pretax Income
Net Earnings	-$992.4K	-$1.344M	-$9.915M
YoY Change	-36.82%	-86.44%
Net Earnings / Revenue	-183.35%	-359.12%	-6007.9%
Basic Earnings Per Share		-$0.11	-$0.82
Diluted Earnings Per Share	-$0.09	-$0.11	-$824.1K
COMMON SHARES
Basic Shares Outstanding	12.25M shares	12.25M shares	12.03M shares
Diluted Shares Outstanding		12.25M shares	12.03M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.645M	$1.770M	$2.529M
YoY Change	-44.77%	-30.02%
Cash & Equivalents	$1.645M	$1.770M	$10.73M
Short-Term Investments
Other Short-Term Assets	$0.00	$0.00	$8.207M
YoY Change	-100.0%	-100.0%
Inventory
Prepaid Expenses
Receivables	$49.77K	$86.26K	$38.67K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.695M	$1.856M	$10.77M
YoY Change	-43.88%	-82.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$186.3K	$145.1K	$25.84K
YoY Change	713.08%	461.58%
Goodwill	$5.805M	$5.805M
YoY Change	0.0%
Intangibles	$354.1K	$378.7K
YoY Change	-21.6%
Long-Term Investments
YoY Change
Other Assets	$5.570K	$5.570K	$0.00
YoY Change	0.0%
Total Long-Term Assets	$6.385M	$6.376M	$6.291M
YoY Change	1.59%	1.36%
TOTAL ASSETS
Total Short-Term Assets	$1.695M	$1.856M	$10.77M
Total Long-Term Assets	$6.385M	$6.376M	$6.291M
Total Assets	$8.080M	$8.232M	$17.07M
YoY Change	-13.17%	-51.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$245.5K	$279.4K	$225.5K
YoY Change	-2.11%	23.9%
Accrued Expenses	$4.658M	$4.190M	$1.514M
YoY Change	118.73%	176.78%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$407.0K
YoY Change	-100.0%	-100.0%
Long-Term Debt Due	$7.047M	$1.532M
YoY Change	361.26%
Total Short-Term Liabilities	$12.00M	$6.077M	$10.35M
YoY Change	184.48%	-41.26%
LONG-TERM LIABILITIES
Long-Term Debt	$8.062M	$13.15M	$12.23M
YoY Change	-31.94%	7.51%
Other Long-Term Liabilities	$1.400K	$8.840K
YoY Change
Total Long-Term Liabilities	$8.063M	$13.16M	$12.23M
YoY Change	-31.93%	7.58%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.00M	$6.077M	$10.35M
Total Long-Term Liabilities	$8.063M	$13.16M	$12.23M
Total Liabilities	$20.06M	$19.23M	$22.57M
YoY Change	24.9%	-14.8%
SHAREHOLDERS EQUITY
Retained Earnings	-$52.18M	-$51.18M
YoY Change	11.8%
Common Stock	$12.44K	$12.25K
YoY Change	2.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$11.98M	-$11.00M	-$5.509M
YoY Change
Total Liabilities & Shareholders Equity	$8.080M	$8.232M	$17.07M
YoY Change	-13.17%	-51.76%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$992.4K	-$1.344M	-$9.915M
YoY Change	-36.82%	-86.44%
Depreciation, Depletion And Amortization	$50.56K	$39.88K	$12.95K
YoY Change	83.79%	207.97%
Cash From Operating Activities	-$49.43K	-$152.2K	-$430.7K
YoY Change	-99.44%	-64.66%
INVESTING ACTIVITIES
Capital Expenditures	$68.53K	-$1.260K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$916.7K
YoY Change	-100.0%	-100.0%
Cash From Investing Activities	-$68.53K	-$1.260K	$916.7K
YoY Change	37972.22%	-100.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-6.500K	-1.460K	-250.5K
YoY Change	-100.65%	-99.42%
NET CHANGE
Cash From Operating Activities	-49.43K	-152.2K	-430.7K
Cash From Investing Activities	-68.53K	-1.260K	916.7K
Cash From Financing Activities	-6.500K	-1.460K	-250.5K
Net Change In Cash	-124.5K	-154.9K	235.5K
YoY Change	-98.39%	-165.77%
FREE CASH FLOW
Cash From Operating Activities	-$49.43K	-$152.2K	-$430.7K
Capital Expenditures	$68.53K	-$1.260K
Free Cash Flow	-$118.0K	-$150.9K
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2021Q4	us-gaap	Other Assets OtherAssets	5568	usd
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	20442	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	7800	usd
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	11802736	usd
CY2021Q4	mssv	Preferred Stock Value1 PreferredStockValue1	1050	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	10	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	12086	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	39899491	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-46669643	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-6757006	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9305566	usd
	dei	Local Phone Number LocalPhoneNumber	889-9509
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-56010
	dei	Entity Registrant Name EntityRegistrantName	MESO NUMISMATICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	88-0492191
	dei	Entity Address Address Line1 EntityAddressAddressLine1	433 Plaza Real Suite 275
	dei	Entity Address City Or Town EntityAddressCityOrTown	Boca Raton
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33432
	dei	City Area Code CityAreaCode	(800)
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
	dei	Security12b Title Security12bTitle	None
	dei	Trading Symbol TradingSymbol	None
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	12250888	shares
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4189504	usd
CY2022Q3	mssv	Customer Advances CustomerAdvances	33990	usd
CY2021Q4	mssv	Customer Advances CustomerAdvances	18215	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1769636	usd
CY2022Q3	us-gaap	Other Receivables OtherReceivables	86262	usd
CY2021Q4	us-gaap	Other Receivables OtherReceivables	17257	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	1855898	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	145112	usd
CY2022Q3	us-gaap	Other Assets OtherAssets	5568	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	378670	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	41408	usd
CY2022Q3	us-gaap	Goodwill Goodwill	5805438	usd
CY2022Q3	us-gaap	Assets Assets	8232094	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	279372	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	251536	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	20000	usd
CY2022Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	9960	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	32568	usd
CY2022Q3	us-gaap	Notes Payable Current NotesPayableCurrent	1531519	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	6076913	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8840	usd
CY2022Q3	mssv	Convertible Notes Payable Net Of Discount ConvertibleNotesPayableNetOfDiscount	38110	usd
CY2022Q3	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	7800	usd
CY2022Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	13100313	usd
CY2022Q3	us-gaap	Liabilities Liabilities	19231976	usd
CY2022Q3	mssv	Preferred Stock Value1 PreferredStockValue1	1050	usd
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	10	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	6500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	6500000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13853202	shares
CY2022Q3	mssv	Common Stock Shares Issuable CommonStockSharesIssuable	13853202	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13687439	shares
CY2021Q4	mssv	Common Stock Shares Issuable CommonStockSharesIssuable	13687439	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12250888	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12085125	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	12251	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	40170862	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-51184055	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-10999882	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8232094	usd
CY2022Q3	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	80931	usd
CY2022Q3	us-gaap	Revenues Revenues	374359	usd
CY2021Q3	us-gaap	Revenues Revenues	165042	usd
	us-gaap	Revenues Revenues	988958	usd
	us-gaap	Revenues Revenues	185254	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	109364	usd
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	88520	usd
	us-gaap	Depreciation Depreciation	102184	usd
	us-gaap	Cost Of Revenue CostOfRevenue	468838	usd
	us-gaap	Cost Of Revenue CostOfRevenue	115170	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	264995	usd
CY2021Q3	us-gaap	Gross Profit GrossProfit	76522	usd
	us-gaap	Gross Profit GrossProfit	520120	usd
	us-gaap	Gross Profit GrossProfit	70084	usd
CY2021Q3	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	518833	usd
	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	67500	usd
	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	552932	usd
CY2022Q3	us-gaap	Depreciation Depreciation	39882	usd
CY2021Q3	us-gaap	Depreciation Depreciation	12947	usd
CY2021Q3	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	22351	usd
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	216506	usd
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	22732	usd
CY2022Q3	us-gaap	Professional Fees ProfessionalFees	143118	usd
CY2021Q3	us-gaap	Professional Fees ProfessionalFees	336299	usd
	us-gaap	Professional Fees ProfessionalFees	735186	usd
	us-gaap	Professional Fees ProfessionalFees	665544	usd
CY2022Q3	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	22500	usd
	us-gaap	Depreciation Depreciation	13347	usd
CY2022Q3	mssv	Investor Relations InvestorRelations	32749	usd
CY2021Q3	mssv	Investor Relations InvestorRelations	32574	usd
	mssv	Investor Relations InvestorRelations	127633	usd
	mssv	Investor Relations InvestorRelations	53046	usd
CY2021Q3	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	8116269	usd
	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	8116269	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	107907	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	52651	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	341131	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	69206	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	427087	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	9091924	usd
	us-gaap	Operating Expenses OperatingExpenses	1590140	usd
	us-gaap	Operating Expenses OperatingExpenses	9493076	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	1183166	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	900039	usd
	us-gaap	Interest Expense InterestExpense	3454874	usd
	us-gaap	Interest Expense InterestExpense	1659724	usd
CY2022Q3	mssv	Settlement Of Lawsuit SettlementOfLawsuit	876	usd
	mssv	Settlement Of Lawsuit SettlementOfLawsuit	10482	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-231109	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1344383	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-9915441	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4514412	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11313825	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.82
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12250888	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12032466	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12187004	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11295486	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-6757006	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	20000	usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	251536	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4514412	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-10999882	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-9655499	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1344383	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-10999882	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-6409571	usd
	mssv	Debt Settlement DebtSettlement	213109	usd
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	963866	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5038576	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	20000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	251536	usd
	mssv	Stock Issued During Period Value Imputed Interest On Debt StockIssuedDuringPeriodValueImputedInterestOnDebt	24192	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	5703537	usd
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Net Income Loss NetIncomeLoss	-11313825	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-5508580	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-1855269	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	251536	usd
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5038576	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	963866	usd
	mssv	Cancellation Of Preferred Series Cc CancellationOfPreferredSeriesCC	83731	usd
CY2021Q3	mssv	Stock Issued During Period Value Imputed Interest On Debt StockIssuedDuringPeriodValueImputedInterestOnDebt	8152	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-9915441	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-5508580	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4514412	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11313825	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1319796	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	500338	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	102184	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13347	usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	10482	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-213109	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	20000	usd
	mssv	Preferred Shares Issued For Services PreferredSharesIssuedForServices	251536	usd
	mssv	Imputed Interest On Debt ImputedInterestOnDebt	24192	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	69007	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5804	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-2714	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	7000	usd
	mssv	Increase Decrease Stock Payable IncreaseDecreaseStockPayable	251536	usd
	us-gaap	Increase Decrease In Due To Affiliates IncreaseDecreaseInDueToAffiliates	8116269	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2104501	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	806467	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1064706	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1129835	usd
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	666647	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	129901	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-129901	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	666647	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	11400000	usd
	mssv	Proceeds From Note Receivable ProceedsFromNoteReceivable	250000	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	14282	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	454	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-14282	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11149546	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1208889	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	10686358	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2978525	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	42534	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1769636	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10728892	usd
	us-gaap	Interest Paid Net InterestPaidNet	265	usd
	mssv	Issuance Of Preferred Series Dd IssuanceOfPreferredSeriesDD	251536	usd
	mssv	Issuance Of Common Shares For Services IssuanceOfCommonSharesForServices	20000	usd
	mssv	Debt Restructure DebtRestructure	5703537	usd
	mssv	Cancellations Of Preferred Series Bb CancellationsOfPreferredSeriesBB	279	usd
	mssv	Shares Issued For Legal Settlement SharesIssuedForLegalSettlement	213109	usd
	mssv	Issuance Of Preferred Series Aa For Acquisition IssuanceOfPreferredSeriesAAForAcquisition	963866	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	175000	usd
	mssv	Discount Issued On Convertible Debt DiscountIssuedOnConvertibleDebt	1200000	usd
	mssv	Issuance Of Preferred Series Dd For Acquisition IssuanceOfPreferredSeriesDDForAcquisition	5038576	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	0	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	0	usd
CY2017Q3	mssv	Share Issuance Of Series Bb Preferred ShareIssuanceOfSeriesBBPreferred	25000	shares
CY2018Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On July 2, 2018, the Board of Directors authorized and shareholders approved a 1-for-1,000 reverse stock split of its issued and outstanding shares of common stock held by the holders of record. The prior year financials have been changed to reflect the 1-for-1,000 reverse stock split.
	mssv	Bear Interest Rate Description BearInterestRateDescription	●Assumed certain Convertible Redeemable Notes issued by Lans Holdings Inc. to a lender, pursuant to the Assignment and Assumption Agreement and subject to any pre-existing defaults under the Notes, Meso Numismatics, Inc. reissued an aggregate of $1,079,626 of Convertible Redeemable Notes to the lender which bear interest at a rate varying from ten (10%) to fifteen (15%) percent, and have a one (1) year maturity date.
	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	1163357	usd
	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	1079626	usd
	mssv	Gross Profits GrossProfits	0.5259	pure
CY2021Q3	mssv	Purchase Agreement Acquiring Description PurchaseAgreementAcquiringDescription	On August 18, 2021, the Company completed its acquisition of Global Stem Cells Group Inc., through a Stock Purchase Agreement acquiring all the outstanding capital stock of Global Stem Cells Group Inc and paid the purchase price of a total of 1,000,000 shares of Series AA Preferred Stock in the Company, 8,974 shares of Series DD Preferred Stock in the Company and $225,000 USD (the final payment of $50,000 was made on July 2, 2021).
	mssv	Issuance Shares IssuanceShares	1000	usd
	mssv	Cash Payments CashPayments	8200000	usd
	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	8200000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Use of Estimates in Financial Statement Presentation</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Reclassifications</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain amounts for the prior year have been revised or reclassified to conform to the current year presentation. No change in net loss resulted from these reclassifications.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p>
	us-gaap	Federal Deposit Insurance Corporation Premium Expense FederalDepositInsuranceCorporationPremiumExpense	250000	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001760026
CY2022Q3	mssv	Convertible Notes Outstanding ConvertibleNotesOutstanding	296864	shares
CY2021Q4	mssv	Convertible Notes Outstanding ConvertibleNotesOutstanding	75710	shares
CY2022Q3	mssv	Convertible Preferred Stock Outstanding ConvertiblePreferredStockOutstanding	37647060	shares
CY2021Q4	mssv	Convertible Preferred Stock Outstanding ConvertiblePreferredStockOutstanding	37647060	shares
CY2022Q3	mssv	Shares Underlying Warrants Outstanding SharesUnderlyingWarrantsOutstanding	103500000	shares
CY2021Q4	mssv	Shares Underlying Warrants Outstanding SharesUnderlyingWarrantsOutstanding	103500000	shares
CY2022Q3	mssv	Total Outstanding TotalOutstanding	141443924	shares
CY2021Q4	mssv	Total Outstanding TotalOutstanding	141222770	shares
CY2022Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	9960	usd
CY2022Q3	us-gaap	Financial Instruments Owned At Fair Value FinancialInstrumentsOwnedAtFairValue	9960	usd
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	20442	usd
CY2021Q4	us-gaap	Financial Instruments Owned At Fair Value FinancialInstrumentsOwnedAtFairValue	20442	usd
CY2022Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Deferred Revenue BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue	8232094	usd
	us-gaap	Profit Loss ProfitLoss	-4514412	usd
CY2019Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.2
	mssv	Going Concern GoingConcern	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Going Concern</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses since inception, resulting in an accumulated deficit of approximately $51 million and a working capital deficit of $4,221,016 as of September 30, 2022 and future losses are anticipated. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ability of the Company to continue its operations as a going concern is dependent on management’s plans, which include the raising of capital through debt and/or equity markets with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company will require additional funding to finance the growth of its current and expected future operations as well to achieve its strategic objectives. There can be no assurance that financing will be available in amounts or terms acceptable to the Company, if at all. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.</p>
CY2022Q3	mssv	Accumulated Deficit AccumulatedDeficit	51000000	usd
CY2022Q3	mssv	Working Capital Deficit WorkingCapitalDeficit	4221016	usd
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	468838	usd
	mssv	Revenue Gross Profits RevenueGrossProfits	520120	usd
	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	988958	usd
	mssv	Description Of Convertible Debentures DescriptionOfConvertibleDebentures	The notes are convertible, at the investors’ sole discretion, into shares of common stock at conversion price equal to the lowest bid price of the Common Stock as reported on the National Quotations Bureau OTC Markets exchange for the three prior trading days including the day upon which a Notice of Conversion is received by the Company.
CY2019Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	81043	shares
CY2019Q4	mssv	Aggregate Exchange Amount AggregateExchangeAmount	97252	usd
	mssv	Payments On The Outstanding Convertible Notes PaymentsOnTheOutstandingConvertibleNotes	10000	usd
CY2021	mssv	Payments On The Outstanding Convertible Notes PaymentsOnTheOutstandingConvertibleNotes	25000	usd
CY2022Q3	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	251144	usd
CY2021Q4	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	251144	usd
CY2022Q3	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	62252	usd
CY2021Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	72252	usd
CY2015	mssv	Debt Instrument Bears Interest Rate DebtInstrumentBearsInterestRate	0.10	pure
CY2022Q3	us-gaap	Principal Amount Outstanding On Loans Securitized PrincipalAmountOutstandingOnLoansSecuritized	130025	usd
	us-gaap	Long Term Debt Contingent Payment Of Principal Or Interest LongTermDebtContingentPaymentOfPrincipalOrInterest	$89,323
CY2019Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	1.2
CY2019Q4	mssv	Premium Paid PremiumPaid	0.20	pure
CY2020Q4	mssv	Promissory Debentures Description PromissoryDebenturesDescription	At December 7, 2020 the Company exchanged $5,379,624 of principal, default penalty and accrued but unpaid interest on convertible notes for $5,379,624 promissory notes and cashless warrants to purchase 15,000,000 shares of our common stock with three separate lenders. The new notes have a maturity date of November 23, 2023 and an aggregate principal amount of $5,379,624 shall bear interest at a fifteen (15%) percentage compounded annual interest rate and, as an incentive; we have issued cashless warrants to purchase 15,000,000 shares of our common stock at an exercise price of $0.03 per share in connection with the restructuring. The Company recorded the fair value of the 15,000,000 warrants issued with debt at approximately $262,376 at December 31, 2020 as a discount. Lender is granted security interest and lien in all rights, title and interest in the assets and property of the as collateral.
CY2020Q4	mssv	Promissory Debentures Description PromissoryDebenturesDescription	the Company entered into a Promissory Debentures with a lender in the amount of $110,000 which bear compounded annual interest at eighteen (18%) percent and have a two (2) year maturity date and cashless warrants to purchase 1,000,000 shares of our common stock. The notes may be repaid in whole or in part at any time prior to maturity. The lender had advanced a total of $100,000, net of discount in the amount of $10,000 to the Company. The Company recorded the fair value of the 1,000,000 warrants issued with debt at approximately $17,491 at December 31, 2020 as a discount. On January 6, 2021, the Company entered into a Promissory Debentures with a lender in the amount of $1,000,000 which bear interest at fifteen (15%) percent and have a one (1) year maturity date and cashless warrants to purchase 10,000,000 shares of our common stock, at exercise prices of $0.03 per share. The notes may be repaid in whole or in part at any time prior to maturity. The lender had advanced a total of $900,000, net of discount in the amount of $100,000 to the Company. The Company recorded the fair value of the 10,000,000 warrants issued with debt at approximately $237,811 at the date of issuance as a discount. This debt instrument is currently in default as of January 6, 2022. On June 22, 2021, the Company entered into a Promissory Debentures with a lender in the amount of $11,600,000 which bear interest at twelve (12%) percent and have a three (3) year maturity date and cashless warrants to purchase 70,000,000 shares of our common stock, at exercise prices of $0.10 per share. The notes may be repaid in whole or in part at any time prior to maturity. The lender had advanced a total of $10,500,000, net of discount in the amount of $1,100,000 to the Company. The Company recorded the fair value of the 70,000,000 warrants issued with debt at approximately $5,465,726 at the date the warrants were issued as a discount. Lender is granted senior security interest and lien in all rights, title and interest in the assets and property of the Company as collateral. On August 18, 2021, through a Stock Purchase Agreement in which 100% of the outstanding shares of Global Stem Cell Group, Inc. the Company acquired a 2018 Jaguar F-Pace which was acquired from Benito Novas for $45,000 on January 8, 2019 and assumed the related auto loan, with an original loan amount of $20,991 at 8.99% interest for 48 months and monthly payments of $504.94. As of September 30, 2022, the principal balance of the outstanding auto loan was $1,494. On August 18, 2021, through a Stock Purchase Agreement in which 100% of the outstanding shares of Global Stem Cell Group, Inc. the Company assumed the November 17, 2020, agreement with an Investor for proceeds in the amount of $400,000 treated as a promissory note. In exchange for the gross proceeds, the Investor shall receive the right to a perpetual 7.75% (payment percentage) of the revenues of Global Stem Cell Group. The payments of the payment percentage shall be calculated by multiplying the gross quarterly revenues appearing in the financial statements by the payment percentage and treated as accrued interest. Payments shall be made ninety (90) days from the end of each respective fiscal quarter with the first payment to be made on the quarter ending December 31, 2020. Payments may be accrued and deferred if payment would deplete cash, cash equivalent and/or short term investment balances on each respective fiscal quarter by more than twenty (20%) percent. As of September 30, 2022, the principal balance of the outstanding loan was $400,000 and accrued interest totals $161,892. This debt instrument is currently in default due to the non-payment of interest. On September 20, 2021, the Company entered into a Promissory Debentures with a lender in the amount of $1,100,000 which bear interest at twelve (12%) percent and have a three (3) year maturity date and cashless warrants to purchase 7,500,000 shares of our common stock, at exercise prices of $0.085 per share. The notes may be repaid in whole or in part at any time prior to maturity. The lender had advanced a total of $1,000,000, net of discount in the amount of $100,000 to the Company. The Company recorded the fair value of the 7,500,000 warrants issued with debt at approximately $360,607 at the time of issuance as a discount. On December 30, 2021, the parties wished to modify the terms of the Promissory Debentures dated July 13, 2020 in the amount of $6,000 and accrued interest in the amount of $1,578 by issuing a new promissory note and extend the date of maturity. In consideration for the new terms, the Promissory Debenture dated December 30, 2021 shall include a five (5%) percent premium for a total of $7,958 which bear interest at twelve (12%) percent and have a seventeen (17) months maturity date. The notes may be repaid in whole or in part at any time prior to maturity. On December 30, 2021, the parties wished to modify the terms of the Promissory Debentures dated July 15, 2020 in the amount of $84,000 and accrued interest in the amount of $22,162 by issuing a new promissory note and extend the date of maturity. In consideration for the new terms, the Promissory Debenture dated December 30, 2021 shall include a five (5%) percent premium for a total of $111,470 which bear interest at twelve (12%) percent and have a seventeen (17) months maturity date. The notes may be repaid in whole or in part at any time prior to maturity.
CY2021Q1	mssv	Promissory Debentures Description PromissoryDebenturesDescription	On January 6, 2021, the Company entered into a Promissory Debentures with a lender in the amount of $1,000,000 which bear interest at fifteen (15%) percent and have a one (1) year maturity date and cashless warrants to purchase 10,000,000 shares of our common stock, at exercise prices of $0.03 per share. The notes may be repaid in whole or in part at any time prior to maturity. The lender had advanced a total of $900,000, net of discount in the amount of $100,000 to the Company. The Company recorded the fair value of the 10,000,000 warrants issued with debt at approximately $237,811 at the date of issuance as a discount. This debt instrument is currently in default as of January 6, 2022. On June 22, 2021, the Company entered into a Promissory Debentures with a lender in the amount of $11,600,000 which bear interest at twelve (12%) percent and have a three (3) year maturity date and cashless warrants to purchase 70,000,000 shares of our common stock, at exercise prices of $0.10 per share. The notes may be repaid in whole or in part at any time prior to maturity. The lender had advanced a total of $10,500,000, net of discount in the amount of $1,100,000 to the Company. The Company recorded the fair value of the 70,000,000 warrants issued with debt at approximately $5,465,726 at the date the warrants were issued as a discount. Lender is granted senior security interest and lien in all rights, title and interest in the assets and property of the Company as collateral. On August 18, 2021, through a Stock Purchase Agreement in which 100% of the outstanding shares of Global Stem Cell Group, Inc. the Company acquired a 2018 Jaguar F-Pace which was acquired from Benito Novas for $45,000 on January 8, 2019 and assumed the related auto loan, with an original loan amount of $20,991 at 8.99% interest for 48 months and monthly payments of $504.94. As of September 30, 2022, the principal balance of the outstanding auto loan was $1,494. On August 18, 2021, through a Stock Purchase Agreement in which 100% of the outstanding shares of Global Stem Cell Group, Inc. the Company assumed the November 17, 2020, agreement with an Investor for proceeds in the amount of $400,000 treated as a promissory note. In exchange for the gross proceeds, the Investor shall receive the right to a perpetual 7.75% (payment percentage) of the revenues of Global Stem Cell Group. The payments of the payment percentage shall be calculated by multiplying the gross quarterly revenues appearing in the financial statements by the payment percentage and treated as accrued interest. Payments shall be made ninety (90) days from the end of each respective fiscal quarter with the first payment to be made on the quarter ending December 31, 2020. Payments may be accrued and deferred if payment would deplete cash, cash equivalent and/or short term investment balances on each respective fiscal quarter by more than twenty (20%) percent. As of September 30, 2022, the principal balance of the outstanding loan was $400,000 and accrued interest totals $161,892. This debt instrument is currently in default due to the non-payment of interest. On September 20, 2021, the Company entered into a Promissory Debentures with a lender in the amount of $1,100,000 which bear interest at twelve (12%) percent and have a three (3) year maturity date and cashless warrants to purchase 7,500,000 shares of our common stock, at exercise prices of $0.085 per share. The notes may be repaid in whole or in part at any time prior to maturity. The lender had advanced a total of $1,000,000, net of discount in the amount of $100,000 to the Company. The Company recorded the fair value of the 7,500,000 warrants issued with debt at approximately $360,607 at the time of issuance as a discount. On December 30, 2021, the parties wished to modify the terms of the Promissory Debentures dated July 13, 2020 in the amount of $6,000 and accrued interest in the amount of $1,578 by issuing a new promissory note and extend the date of maturity. In consideration for the new terms, the Promissory Debenture dated December 30, 2021 shall include a five (5%) percent premium for a total of $7,958 which bear interest at twelve (12%) percent and have a seventeen (17) months maturity date. The notes may be repaid in whole or in part at any time prior to maturity. On December 30, 2021, the parties wished to modify the terms of the Promissory Debentures dated July 15, 2020 in the amount of $84,000 and accrued interest in the amount of $22,162 by issuing a new promissory note and extend the date of maturity. In consideration for the new terms, the Promissory Debenture dated December 30, 2021 shall include a five (5%) percent premium for a total of $111,470 which bear interest at twelve (12%) percent and have a seventeen (17) months maturity date. The notes may be repaid in whole or in part at any time prior to maturity.
	mssv	Market Value Of Common Stock On Measurement Datein Dollars MarketValueOfCommonStockOnMeasurementDateinDollars	0.03
	mssv	Adjusted Exercise Pricein Dollars Per Share AdjustedExercisePriceinDollarsPerShare	0.06
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0379	pure
	mssv	Instrument Lives In Years InstrumentLivesInYears	P2Y3M
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.05	pure
CY2021Q2	mssv	Promissory Debentures Description PromissoryDebenturesDescription	the Company entered into a Promissory Debentures with a lender in the amount of $11,600,000 which bear interest at twelve (12%) percent and have a three (3) year maturity date and cashless warrants to purchase 70,000,000 shares of our common stock, at exercise prices of $0.10 per share. The notes may be repaid in whole or in part at any time prior to maturity. The lender had advanced a total of $10,500,000, net of discount in the amount of $1,100,000 to the Company. The Company recorded the fair value of the 70,000,000 warrants issued with debt at approximately $5,465,726 at the date the warrants were issued as a discount. Lender is granted senior security interest and lien in all rights, title and interest in the assets and property of the Company as collateral.On August 18, 2021, through a Stock Purchase Agreement in which 100% of the outstanding shares of Global Stem Cell Group, Inc. the Company acquired a 2018 Jaguar F-Pace which was acquired from Benito Novas for $45,000 on January 8, 2019 and assumed the related auto loan, with an original loan amount of $20,991 at 8.99% interest for 48 months and monthly payments of $504.94. As of September 30, 2022, the principal balance of the outstanding auto loan was $1,494. On August 18, 2021, through a Stock Purchase Agreement in which 100% of the outstanding shares of Global Stem Cell Group, Inc. the Company assumed the November 17, 2020, agreement with an Investor for proceeds in the amount of $400,000 treated as a promissory note. In exchange for the gross proceeds, the Investor shall receive the right to a perpetual 7.75% (payment percentage) of the revenues of Global Stem Cell Group. The payments of the payment percentage shall be calculated by multiplying the gross quarterly revenues appearing in the financial statements by the payment percentage and treated as accrued interest. Payments shall be made ninety (90) days from the end of each respective fiscal quarter with the first payment to be made on the quarter ending December 31, 2020. Payments may be accrued and deferred if payment would deplete cash, cash equivalent and/or short term investment balances on each respective fiscal quarter by more than twenty (20%) percent. As of September 30, 2022, the principal balance of the outstanding loan was $400,000 and accrued interest totals $161,892. This debt instrument is currently in default due to the non-payment of interest. On September 20, 2021, the Company entered into a Promissory Debentures with a lender in the amount of $1,100,000 which bear interest at twelve (12%) percent and have a three (3) year maturity date and cashless warrants to purchase 7,500,000 shares of our common stock, at exercise prices of $0.085 per share. The notes may be repaid in whole or in part at any time prior to maturity. The lender had advanced a total of $1,000,000, net of discount in the amount of $100,000 to the Company. The Company recorded the fair value of the 7,500,000 warrants issued with debt at approximately $360,607 at the time of issuance as a discount. On December 30, 2021, the parties wished to modify the terms of the Promissory Debentures dated July 13, 2020 in the amount of $6,000 and accrued interest in the amount of $1,578 by issuing a new promissory note and extend the date of maturity. In consideration for the new terms, the Promissory Debenture dated December 30, 2021 shall include a five (5%) percent premium for a total of $7,958 which bear interest at twelve (12%) percent and have a seventeen (17) months maturity date. The notes may be repaid in whole or in part at any time prior to maturity. On December 30, 2021, the parties wished to modify the terms of the Promissory Debentures dated July 15, 2020 in the amount of $84,000 and accrued interest in the amount of $22,162 by issuing a new promissory note and extend the date of maturity. In consideration for the new terms, the Promissory Debenture dated December 30, 2021 shall include a five (5%) percent premium for a total of $111,470 which bear interest at twelve (12%) percent and have a seventeen (17) months maturity date. The notes may be repaid in whole or in part at any time prior to maturity.
CY2021Q3	mssv	Promissory Debentures Description PromissoryDebenturesDescription	On September 20, 2021, the Company entered into a Promissory Debentures with a lender in the amount of $1,100,000 which bear interest at twelve (12%) percent and have a three (3) year maturity date and cashless warrants to purchase 7,500,000 shares of our common stock, at exercise prices of $0.085 per share. The notes may be repaid in whole or in part at any time prior to maturity. The lender had advanced a total of $1,000,000, net of discount in the amount of $100,000 to the Company. The Company recorded the fair value of the 7,500,000 warrants issued with debt at approximately $360,607 at the time of issuance as a discount.
	mssv	Promissory Notes Payable PromissoryNotesPayable	20239053	usd
CY2021	mssv	Promissory Notes Payable PromissoryNotesPayable	20243335	usd
	mssv	Promissory Notes Payable Discount PromissoryNotesPayableDiscount	5541887	usd
CY2021	mssv	Promissory Notes Payable Discount PromissoryNotesPayableDiscount	6822622	usd
CY2022Q3	us-gaap	Other Deferred Costs Gross OtherDeferredCostsGross	57534	usd
CY2021Q4	us-gaap	Other Deferred Costs Gross OtherDeferredCostsGross	82466	usd
CY2022Q3	us-gaap	Notes Payable NotesPayable	14639632	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	13338247	usd
	us-gaap	Dividends Share Based Compensation Cash DividendsShareBasedCompensationCash	14282	usd
CY2021	us-gaap	Dividends Share Based Compensation Cash DividendsShareBasedCompensationCash	1812	usd
	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	2135079	usd
CY2021	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	1781394	usd
	us-gaap	Investment Income Amortization Of Discount InvestmentIncomeAmortizationOfDiscount	1280736	usd
CY2021	us-gaap	Investment Income Amortization Of Discount InvestmentIncomeAmortizationOfDiscount	874476	usd
CY2022Q3	us-gaap	Interest Payable Current InterestPayableCurrent	3938360	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1878251	usd
CY2022Q3	mssv	Outstanding Promissory Notes Payable OutstandingPromissoryNotesPayable	20239055	usd
CY2021Q4	mssv	Outstanding Promissory Notes Payable OutstandingPromissoryNotesPayable	20243335	usd
	mssv	Common Stock Issuablein Shares CommonStockIssuableinShares	296864	shares
CY2021	mssv	Derivative Instruments Additions DerivativeInstrumentsAdditions	24186	usd
CY2021Q4	mssv	Gain On Derivative Instruments GainOnDerivativeInstruments	-3744	usd
CY2021Q4	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	20442	usd
CY2022Q3	mssv	Gain On Derivative Instruments GainOnDerivativeInstruments	-8627	usd
	mssv	Derivative Instruments Conversions DerivativeInstrumentsConversions	-1855	usd
CY2022Q3	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	9960	usd
	us-gaap	Debt Conversion Description DebtConversionDescription	At any time prior to November 25, 2022 (“Automatic Conversion Date”) the Company may redeem for cash out of funds legally available therefore, any or all of the outstanding Series CC Convertible Preferred Stock at a price equal to $1,000 per share. If not converted prior, on the Automatic Conversion Date, any and all remaining issued and outstanding shares of Series CC Convertible Preferred Stock shall automatically convert at the Conversion Price, which is a price per share determined by dividing the number of issued and outstanding shares of (common) stock of the Company on the date of conversion by 1,000 and multiply the results by 0.8.
CY2022Q2	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	89485	shares
CY2022Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	10000	usd
CY2021Q1	mssv	Issuance Of Warrants IssuanceOfWarrants	10000000	shares
CY2021Q1	mssv	Warrants Issued For Debt WarrantsIssuedForDebt	237811	usd
CY2021Q2	mssv	Issuance Of Warrants IssuanceOfWarrants	70000000	shares
CY2021Q2	mssv	Warrants Issued For Debt WarrantsIssuedForDebt	5465726	usd
CY2021Q3	mssv	Issuance Of Warrants IssuanceOfWarrants	7500000	shares
CY2021Q3	mssv	Warrants Issued For Debt WarrantsIssuedForDebt	360607	usd
CY2014Q2	mssv	Aggregate Vote AggregateVote	0.67	pure
CY2021Q3	mssv	Final Payment FinalPayment	225000	usd
CY2021Q3	mssv	Final Payment FinalPayment	50000	usd
	mssv	Convertible Common Stock Description ConvertibleCommonStockDescription	The Series AA Preferred shares issued on August 18, 2021, were valued based upon industry specific control premiums and the Company’s market cap at the time of the transaction. The $963,866 value of the 1,000,000 shares of Series AA Super Voting Preferred Stock issued to Benito Novas were valued based on a calculation by a third party independent valuation specialist.
	mssv	Professional Service Consulting Description ProfessionalServiceConsultingDescription	In consideration of mutual covenants set forth in the Professional Service Consulting Agreement, Dave Christensen, current Director, President, Chief Executive Officer, Chief Financial Officer and Secretary, shall be compensated monthly based on annual rate of $90,000, starting January 1, 2022. Additionally, the agreement included an issuance of 896 shares of Series DD Preferred Stock of the Company. An amount of 448 shares were issued on August 18, 2021 and the remaining 448 were issued February 18, 2022.
	us-gaap	Other Expenses OtherExpenses	503552	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	251776	usd
CY2022Q1	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	448	shares
CY2021	mssv	Recorded As Stock Payable RecordedAsStockPayable	251536	usd
	mssv	Professional Service Consulting Agreement Description ProfessionalServiceConsultingAgreementDescription	In consideration of mutual covenants set forth in the Professional Service Consulting Agreement, Dave Christensen, current Director, President, Chief Executive Officer, Chief Financial Officer and Secretary, shall be compensated monthly based on annual rate of $90k starting January 1, 2022. Additionally, the agreement includes an issuance of 896 shares of Series DD Preferred Stock of the Company. An amount of 448 shares were issued on August 18, 2021 and the remaining 448 were issued February 18, 2022.
	us-gaap	Payments For Fees PaymentsForFees	22500	usd
CY2021Q4	us-gaap	Escrow Deposit Disbursements Related To Property Acquisition1 EscrowDepositDisbursementsRelatedToPropertyAcquisition1	8200000	usd
CY2021Q3	mssv	Stock Purchase Agreement Percentage StockPurchaseAgreementPercentage	1	pure
CY2019Q1	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	20991	usd
CY2021Q1	us-gaap	Payments For Proceeds From Deposit On Loan PaymentsForProceedsFromDepositOnLoan	504.94	usd
	mssv	Outstanding Auto Loan OutstandingAutoLoan	1494	usd
CY2021Q3	mssv	Outstanding Share Percentage OutstandingSharePercentage	1	pure
	mssv	Aggregate Amount AggregateAmount	119143	usd
CY2017	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	282500	usd
CY2021Q2	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	300000	usd
CY2021Q2	mssv	Issued Shares Of Common Stock IssuedSharesOfCommonStock	1092866	shares
CY2021Q2	mssv	Common Stock Settlement Amount CommonStockSettlementAmount	213109	usd
CY2021Q2	us-gaap	Certain Loans Acquired In Transfer Accounted For As Debt Securities Outstanding Balance CertainLoansAcquiredInTransferAccountedForAsDebtSecuritiesOutstandingBalance	0	usd
	us-gaap	Effective Income Tax Rate Reconciliation Disposition Of Assets EffectiveIncomeTaxRateReconciliationDispositionOfAssets	0.275	pure
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	72766	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	43536	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	145112	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22909	usd
	mssv	Equipment And Leaseholds Purchased EquipmentAndLeaseholdsPurchased	121332	usd
CY2022Q3	mssv	Equipment And Leaseholds Purchased EquipmentAndLeaseholdsPurchased	28838	usd
	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	29230	usd
	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	1856	usd
CY2021Q3	mssv	Outstanding Shares Percentage OutstandingSharesPercentage	1	pure
CY2021Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	225000	usd
	us-gaap	Convertible Preferred Stock Terms Of Conversion ConvertiblePreferredStockTermsOfConversion	The preliminary purchase price for the merger was determined to be $6.229 million, which consists of (i) 1 million shares of Series AA preferred stock valued at approximately $964,000, (ii) 8,974 shares of Series DD preferred stock valued at approximately $5.04 million and (iii) $225,000 in cash of which $175,000 was advanced in prior to closing of the transaction.
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	1089976	usd
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-12999298	usd
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-1.13
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	43425	usd
CY2022Q3	us-gaap	Receivable With Imputed Interest Net Amount ReceivableWithImputedInterestNetAmount	2016	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	41409	usd
CY2022Q3	us-gaap	Finite Lived Trademarks Gross FiniteLivedTrademarksGross	87700	usd
CY2021Q4	us-gaap	Finite Lived Trademarks Gross FiniteLivedTrademarksGross	87700	usd
	mssv	Intellectual Property Licenses IntellectualPropertyLicenses	363000	usd
CY2021	mssv	Intellectual Property Licenses IntellectualPropertyLicenses	363000	usd
	mssv	Customer Base CustomerBase	37000	usd
CY2021	mssv	Customer Base CustomerBase	37000	usd
CY2022Q3	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	487700	usd
CY2021Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	487700	usd
CY2022Q3	us-gaap	Capitalized Computer Software Accumulated Amortization CapitalizedComputerSoftwareAccumulatedAmortization	109030	usd
CY2021Q4	us-gaap	Capitalized Computer Software Accumulated Amortization CapitalizedComputerSoftwareAccumulatedAmortization	36076	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	378670	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	451624	usd
	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P5Y
	mssv	Amortization Expense Intellectual Property AmortizationExpenseIntellectualProperty	72954	usd
	mssv	Amortization Expense Intellectual Property AmortizationExpenseIntellectualProperty	11491	usd
	mssv	Monthly Rent MonthlyRent	2714	usd
CY2022Q3	us-gaap	Security Deposit Liability SecurityDepositLiability	5588	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	24427	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	18998	usd
CY2022Q3	us-gaap	Advance Rent AdvanceRent	2714	usd
CY2022Q3	us-gaap	Security Deposit SecurityDeposit	5568	usd
CY2022Q1	us-gaap	Payments To Acquire Water Systems PaymentsToAcquireWaterSystems	121332	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2022Q3	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent		usd
CY2021Q3	mssv	Settlement Of Lawsuit SettlementOfLawsuit		usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12032466	shares
	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue		usd
	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited		usd
CY2021Q3	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited		usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	mssv	Imputed Interest On Debt ImputedInterestOnDebt		usd
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	mssv	Issuance Of Preferred Series Dd IssuanceOfPreferredSeriesDD		usd
	mssv	Issuance Of Common Shares For Services IssuanceOfCommonSharesForServices		usd
	mssv	Debt Restructure DebtRestructure		usd
	mssv	Cancellations Of Preferred Series Bb CancellationsOfPreferredSeriesBB		usd
	mssv	Shares Issued For Legal Settlement SharesIssuedForLegalSettlement		usd
	mssv	Cancellation Of Preferred Series Cc CancellationOfPreferredSeriesCC		usd
	mssv	Issuance Of Preferred Series Aa For Acquisition IssuanceOfPreferredSeriesAAForAcquisition		usd
	mssv	Issuance Of Preferred Series Dd For Acquisition IssuanceOfPreferredSeriesDDForAcquisition		usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		usd
	mssv	Discount Issued On Convertible Debt DiscountIssuedOnConvertibleDebt		usd
	mssv	Expected Dividend Yields ExpectedDividendYields
CY2020Q4	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet		usd
CY2021	mssv	Derivative Instruments Conversions DerivativeInstrumentsConversions		usd
	mssv	Derivative Instruments Additions DerivativeInstrumentsAdditions		usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree		usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour		usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive		usd
	dei	Amendment Flag AmendmentFlag	false

Files In Submission

Name	View Source	Status
mssv-20220930_cal.xml	Edgar Link	unprocessable
0001213900-22-070224-index-headers.html	Edgar Link	pending
0001213900-22-070224-index.html	Edgar Link	pending
0001213900-22-070224.txt	Edgar Link	pending
0001213900-22-070224-xbrl.zip	Edgar Link	pending
f10q0922ex31-1_mesonum.htm	Edgar Link	pending
f10q0922ex31-2_mesonum.htm	Edgar Link	pending
f10q0922ex32-1_mesonum.htm	Edgar Link	pending
f10q0922_mesonum.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mssv-20220930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
mssv-20220930_def.xml	Edgar Link	unprocessable
mssv-20220930_pre.xml	Edgar Link	unprocessable
mssv-20220930_lab.xml	Edgar Link	unprocessable
f10q0922_mesonum_htm.xml	Edgar Link	completed
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RMTG
Regenerative Medical Technology Group Inc. Stock $rmtg

2022 Q4 Form 10-Q Financial Statement

#000121390022070224 Filed on November 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RMTG Regenerative Medical Technology Group Inc. Stock $rmtg

2022 Q4 Form 10-Q Financial Statement

#000121390022070224 Filed on November 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RMTG
Regenerative Medical Technology Group Inc. Stock $rmtg